5 results match your criteria: "Kyoundo Hospital of the Sasaki Institute[Affiliation]"
Improvement in Quality of Life Following Celiprolol Hydrochloride Administration in a Patient with Vascular Ehlers-Danlos Syndrome: A Case Report.
Ann Vasc Dis
June 2023
Department of Radiology, Kyoundo Hospital of the Sasaki Institute, Tokyo, Japan.
A 40-year-old female, who underwent transcatheter arterial embolization due to acute bleeding from an iliolumbar artery, was subsequently genetically diagnosed with vascular Ehlers-Danlos syndrome. She experienced chronic anemia for many years due to the easy bruising of her whole body. The bruising improved with oral administration of celiprolol hydrochloride.
View Article and Find Full Text PDFBackground: Prior to the approval of sorafenib, hepatic arterial infusion chemotherapy (HAIC) was offered to patients with advanced hepatocellular carcinoma (HCC) in East Asia, particularly Japan. According to the Japanese guidelines, HAIC is recommended as one of the treatment options in patients without extrahepatic metastasis (EHM).
Methods: The present cohort study compared the use of HAIC and sorafenib on outcomes of patients with advanced HCC.
Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon-α combination therapy for hepatocellular carcinoma with extrahepatic metastases.
Hepatol Res
August 2018
Department of Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Article Synopsis
- The study aimed to evaluate the effectiveness of S-1 alone and in combination with interferon (IFN)-α for treating hepatocellular carcinoma (HCC) patients with extrahepatic metastases in a randomized trial.
- It involved 103 patients who were divided into two groups; one received S-1 with IFN-α and the other received S-1 only, with the goal of comparing their clinical efficacy and side effects.
- Results showed no significant differences in treatment response or survival rates between the two groups, although the combination therapy had a higher incidence of severe adverse events.
A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients.
Jpn J Clin Oncol
November 2016
Department of Palliative Nursing, Health Sciences, Tohoku University Graduate School of Medicine, Sendai, Japan.
Objective: Development of hand-foot syndrome symptoms, which is a common adverse effect of several cancer chemotherapy agents, can result in patient withdrawal from treatment. Its early identification allows appropriate modification of chemotherapy regimens and can avert treatment withdrawal by minimizing the impact on quality of life and duration of discontinued therapy. We sought to develop a simple home-based self-monitoring tool to facilitate reliable early identification of hand-foot syndrome, based on the self-administered quality of life questionnaire hand-foot syndrome-14.
View Article and Find Full Text PDFCurrent Status of Hepatic Arterial Infusion Chemotherapy.
Liver Cancer
September 2015
Department of Gastroenterology and Hepatology, Kyoundo Hospital of the Sasaki Institute, Tokyo, Japan.
Background: Hepatic arterial infusion chemotherapy (HAIC) is frequently used to treat advanced hepatocellular carcinoma (HCC) in Asian countries. However, there is a lack of evidence supporting the use of HAIC.
Summary: Many studies report high response rates in patients with advanced HCC receiving HAIC, and clinical responses translate to survival benefits.